Drugs / WJ-MSC
WJ-MSC
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05855707 | Sep 2023 → Sep 2025 overdue | acute graft versus host disease | Central Hospital, Nancy, France | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02963727 | Jan 2017 → Oct 2021 | osteoarthritis, knee | Hanan Jafar | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05054803 | Oct 2021 → Jan 2024 | spinal cord injury | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
| Phase 1/2 | NCT03533153 | Mar 2021 → Dec 2023 | myocardial infarction | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT04390139 | May 2020 → Dec 2022 | COVID-19, adult acute respiratory distress syndrome | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
| Phase 1/2 | NCT03003364 | Dec 2016 → Jul 2019 | spinal cord injury | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05018637 | Sep 2020 → Dec 2022 | osteoporosis, vertebral disorder | Inbo Han | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04877067 Comparator | Apr 2019 → Apr 2021 | methanol poisoning, toxic optic neuropathy | Ankara University Technopolis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJ-MSC | “Wharton's jelly derived mesenchymal stem cells (WJ-MSC) can increase mitochondrial ATP synthesis with paracrine effects and suppress neuroinflammation with immunomodulatory effects.” NCT04877067 ↗5“Wharton Jelly derived Mesenchymal Stem Cells (WJMSC)” NCT02963727 ↗ |
| Known as | Wharton Jelly derived mesenchymal stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02963727 ↗ |
| Known as | XCEL-UMC-BETA | “WJ-MSC (XCEL-UMC-BETA)” NCT05054803 ↗ |
| Modality | Cell therapy | “Wharton Jelly derived Mesenchymal Stem Cells (WJMSC)” NCT02963727 ↗ |
| Route | Intrathecal | “intrathecal administration (L3 level)” NCT03003364 ↗ |